Considering the importance of PIK3CB/p110β in PTEN-deficient tumours and the high frequency of PTEN mutations in endometrial cancer, the effect of p110β selective inhibition was evaluated in endometrial cancer cell lines, with or without PTEN loss [44,113]. This evidence concerns the gene PTEN and endometrial cancer.